SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as the community discusses recent developments including Gravity SUV deliveries in Canada and a partnership with Riyadh Season. Despite positive news, concerns persist around production targets, potential dilution, and the company's overall financial health, fueling debate among investors. Some are optimistic about Lucid's technology and long-term potential, while others express skepticism about its ability to compete effectively in the EV market.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as the quantum computing sector gains momentum, with community members highlighting its undervaluation compared to peers like $RGTI and potential links to $NVDA. Discussions revolve around the upcoming merger with Infleqtion and its participation in the Q+AI Conference 2025 as potential catalysts. Some investors express excitement about the stock's long-term potential, drawing parallels to past SPAC successes.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine ($APPS) is trending as investors discuss its potential in the evolving app store landscape following recent rulings and potential AI partnerships; the community is actively debating whether the stock's current momentum is sustainable and if it can maintain its upward trajectory, with some closely watching for a breakout while short positions may get squeezed. Broader discussions cover the company's restructuring, potential acquisitions, and impact of broader market trends.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending due to positive sentiment around potential upgrades and community excitement about its gains, with some eyeing a move to double digits. Bullish traders are celebrating recent wins and expressing confidence in the stock's undervaluation, citing Wedbush's price target. However, some caution exists regarding potential pullbacks, with a few traders closing positions for profit.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending due to a mix of factors, including recent price volatility and discussions around a potential CEO share sale. The community is debating potential support levels and whether the stock is currently oversold, while also considering the company's broader positioning in the telehealth and pharmaceutical landscape.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences N.V.

ATAI is trending after receiving FDA Breakthrough Therapy Designation for its depression treatment, BPL-003, driving excitement among investors. Community members are discussing Jefferies' raised price target to $10 and the potential for Phase 3 trials, while also weighing the impact of a recent public offering.  The stock is viewed by some as a long-term play in the burgeoning psychedelic medicine sector, drawing comparisons to $TSLA and $NVDA.

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

$FIRECOIN is trending due to increasing attention within the Phantom Wallet community, with many users highlighting its potential for significant gains. The community is actively discussing its availability on Phantom Wallet and anticipating a potential 'moonshot,' while some users are raising concerns about potential scams.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders weigh positive catalysts like potential US-China trade talks against concerns about high valuations and regional banking risks. Community discussions focus on whether the current market action is a bull trap or the start of a sustained rally, with many observing unusual price swings and questioning the influence of algorithmic trading. Some traders are pointing to Trump's comments on China and potential interest rate cuts as bullish signals, while others remain cautious, citing overbought conditions and a potential for a pullback.

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine Inc

Mind Medicine Inc - Ordinary Shares (Sub Voting)

MNMD is trending as the community discusses potential catalysts, including positive trial data and regulatory developments in the psychedelics sector.  Bullish sentiment is fueled by the anticipation of significant price appreciation and potential buyouts, with the company's strong cash position and ongoing Phase 3 trials cited as key factors. Discussions also involve the broader context of psychedelic medicine's growing acceptance and potential to revolutionize mental health treatment.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending due to a mixed reaction to its AI World event and announcements, including a partnership with Meta and ambitious long-term revenue targets. While some analysts are optimistic, concerns linger in the community about near-term profitability, heavy AI capex, and execution risks. Community members are actively discussing potential price movements, upgrades from analysts, and the impact of AI deals on Oracle's future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

Keros Therapeutics (KROS) delivered earnings and revenue surprises of +33.33% and +135.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

KROS vs. EXAS: Which Stock Should Value Investors Buy Now?

KROS vs. EXAS: Which Stock Is the Better Value Option?

Will Reblozyl Enable BMY to Offset the Impact of Generic Competition? 

Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.

FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo

GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.

KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Shares of Keros Therapeutics, Inc. (KROS) traded 14% higher on Thursday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-announces-review-strategic-alternatives">adopted</a> a poison pill plan to fend off hostile takeovers by a number of investors that have rapidly accumulated a significant number of shares in the firm.The defense strategy, a limited-duration stockholder rights plan, will reduce the likelihood that a hostile group gains control of Keros through open-market accumulation without paying all stockholders an appropriate control premium.As per the plan, if any entity acquires ownership of 10% or more, or 15% in the case of passive institutional investors, of Keros’ outstanding common stock in a transaction not approved by the Board, other shareholders can purchase additional shares at a discount.The company adopted the plan after a number of investors who accumulated the company’s common stock indicated a desire to gain control over the firm. This included an individual investor who informed the company that it holds 11.2% of Keros’ outstanding common stock as of April 6, 2025. The company did not name the investor.Keros said that its board has also decided to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the company.A committee will consider a range of strategic alternatives including the sale of the company or other business combination transaction, continued investment in its pipeline, or return of excess capital to stockholders.The company added that there is no assurance the review will lead to the company pursuing a transaction.On Stocktwits, retail sentiment around Keros jumped from ‘neutral’ to ‘extremely bullish’ while message volume rose from ‘low’ to ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:647/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_10_at_11_27_14_AM_png_386737346f.webp" alt="KROS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 10, 2025 | Source: Stocktwits" width="647" height="151"><figcaption>KROS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 10, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/KROS">KROS shares</a> are down by about 26% year-to-date and 81% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/polestar-q1-sales-jump-76-percent-on-newer-models/chfYiCFRbBr">Polestar Q1 Sales Jump 76% On Newer Models: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed

The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control premium.

Equity

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Keros Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

KROS
Keros Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KROS News

KROSKeros Therapeutics Inc